Eveliqure Biotechnologies is focused on developing innovative vaccines aimed at preventing diarrheal diseases, particularly in low- and middle-income countries. Their primary technology revolves around a live attenuated vaccine strain of the bacterium Shigella, which has been genetically engineered to provide broad protection against various species and serotypes of this pathogen. This proprietary platform not only targets Shigella but also incorporates non-Shigella derived antigens, enabling the vaccine to offer immunity against multiple pathogens, including enterotoxigenic Escherichia coli (ETEC). The first candidate from this platform, known as ShigETEC, is designed to elicit protective immunity against both Shigella and ETEC, which are significant contributors to diarrheal diseases.

The administration of Eveliqure's vaccine is intended to be oral and in liquid form, which is expected to stimulate a mucosal immune response critical for preventing enteral infections. This approach is particularly beneficial for populations in endemic regions, as it aims to provide a practical and effective solution to combat the high incidence of diarrheal diseases. By leveraging their advanced vaccine technology, Eveliqure is positioned to make a significant impact on public health, especially in areas where these diseases are prevalent.

Austria

Eveliqure Biotechnologies is an innovative biotech company developing novel vaccines for the prevention of diarrhoeal diseases both for travellers and people living in endemic regions of low- and middle-income countries.Eveliqure is a game-changer amongst vaccine companies, championing novel technologies to make the world safe from diarrhoea. Eveliqure is passionate about improving the quality of life for both the poor and the privileged by providing innovative medical solutions that fight diarrhoeal diseases.

Eveliqure Biotechnologies

Company Details